Rutaecarpine enhances the anti-diabetic activity and hepatic distribution of metformin via up-regulation of Oct1 in diabetic rats

References

• Burt, H., et al., 2016. Metformin and cimetidine: physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. European journal of pharmaceutical sciences, 88, 70–82.
   PubMed Web of Science ®Google Scholar
• Chan, P., et al., 2018. Metformin transporter pharmacogenomics: insights into drug disposition-where are we now? Expert opinion on drug metabolism & toxicology, 14 (11), 1149–1159.
   PubMed Web of Science ®Google Scholar
• El Messaoudi, S., et al., 2011. The cardioprotective effects of metformin. Current opinion in lipidology, 22 (6), 445–453.
   PubMed Web of Science ®Google Scholar
• Elsby, R., et al., 2017. Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (mate) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine. Pharmacology research & perspectives, 5 (5), e00357.
   Web of Science ®Google Scholar
• Gargouri, M., Magné, C., and El Feki, A., 2016. Hyperglycemia, oxidative stress, liver damage and dysfunction in alloxan-induced diabetic rat are prevented by spirulina supplementation. Nutrition research, 36 (11), 1255–1268.
   PubMed Web of Science ®Google Scholar
• Gessner, A., König, J., and Fromm, M., 2019. Clinical aspects of transporter-mediated drug-drug interactions. Clinical pharmacology and therapeutics, 105 (6), 1386–1394.
   PubMed Web of Science ®Google Scholar
• Han, S., et al., 2019. Lonicera japonica extract increases metformin distribution in the liver without change of systemic exposed metformin in rats. Journal of ethnopharmacology, 238, 111892.
   PubMed Web of Science ®Google Scholar
• Higgins, J., Bedwell, D., and Zamek-Gliszczynski, M., 2012. Ablation of both organic cation transporter (oct)1 and oct2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug metabolism and disposition, 40 (6), 1170–1177.
   PubMed Web of Science ®Google Scholar
• Hoffmaster, K., et al., 2004. P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharmaceutical research, 21 (7), 1294–1302.
   PubMed Web of Science ®Google Scholar
• Igel, L., et al., 2016. Metformin: an old therapy that deserves a new indication for the treatment of obesity. Current atherosclerosis reports, 18 (4), 16.
   PubMed Web of Science ®Google Scholar
• Ito, K., et al., 2020. Hepatic transporter alterations by nuclear receptor agonist t0901317 in sandwich-cultured human hepatocytes: proteomic analysis and pbpk modeling to evaluate drug-drug interaction risk. The journal of pharmacology and experimental therapeutics, 373 (2), 261–268.
   PubMed Web of Science ®Google Scholar
• Jensen, J., et al., 2016. [11c]-labeled metformin distribution in the liver and small intestine using dynamic positron emission tomography in mice demonstrates tissue-specific transporter dependency. Diabetes, 65 (6), 1724–1730.
   PubMed Web of Science ®Google Scholar
• Jonker, J., et al., 2003. Deficiency in the organic cation transporters 1 and 2 (oct1/oct2 [slc22a1/slc22a2]) in mice abolishes renal secretion of organic cations. Molecular and cellular biology, 23 (21), 7902–7908.
   PubMed Web of Science ®Google Scholar
• Karbownik, A., et al., 2020. Pharmacokinetic interaction between sorafenib and atorvastatin, and sorafenib and metformin in rats. Pharmaceutics, 12 (7), 600.
   Web of Science ®Google Scholar
• Khodabandehloo, H., et al., 2016. Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction. Translational research, 167 (1), 228–256.
   PubMed Web of Science ®Google Scholar
• Kimura, N., et al., 2005a. Metformin is a superior substrate for renal organic cation transporter oct2 rather than hepatic oct1. Drug metabolism and pharmacokinetics, 20 (5), 379–386.
   PubMedGoogle Scholar
• Kimura, N., Okuda, M., and Inui, K., 2005b. Metformin transport by renal basolateral organic cation transporter hoct2. Pharmaceutical research, 22 (2), 255–259.
   PubMed Web of Science ®Google Scholar
• Ko, H., et al., 2007. Anti-inflammatory effects and mechanisms of the ethanol extract of evodia rutaecarpa and its bioactive components on neutrophils and microglial cells. European journal of pharmacology, 555 (2–3), 211–217.
   PubMed Web of Science ®Google Scholar
• Li, L., et al., 2018. Co-administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter oct1 and mate1. Biopharmaceutics & drug disposition, 39, 411–419.
   PubMed Web of Science ®Google Scholar
• Liang, R., et al., 2020. Involvement of organic anion-transporting polypeptides and organic cation transporter in the hepatic uptake of jatrorrhizine. Xenobiotica, 50 (4), 479–487.
   PubMed Web of Science ®Google Scholar
• Liang, X. and Giacomini, K., 2017. Transporters involved in metformin pharmacokinetics and treatment response. Journal of pharmaceutical sciences, 106 (9), 2245–2250.
   PubMed Web of Science ®Google Scholar
• Liu, G., et al., 2018. Stachyose improves inflammation through modulating gut microbiota of high-fat diet/streptozotocin-induced type 2 diabetes in rats. Molecular nutrition & food research, 62 (6), e1700954.
   PubMed Web of Science ®Google Scholar
• Liu, Y., et al., 2020. Dynamic phenotypes and molecular mechanisms to understand the pathogenesis of diabetic nephropathy in two widely used animal models of type 2 diabetes mellitus. Frontiers in cell and developmental biology, 8, 172.
   PubMed Web of Science ®Google Scholar
• Lu, H., et al., 2015. Recent pharmacokinetic studies in combination therapies for diabetes and related vascular complications. Current vascular pharmacology, 13 (4), 554–561.
   PubMed Web of Science ®Google Scholar
• Luo, J., et al., 2020. Rutaecarpine derivative r3 attenuates atherosclerosis via inhibiting nlrp3 inflammasome-related inflammation and modulating cholesterol transport. FASEB journal, 34 (1), 1398–1411.
   PubMed Web of Science ®Google Scholar
• Madiraju, A., et al., 2018. Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nature medicine, 24 (9), 1384–1394.
   PubMed Web of Science ®Google Scholar
• Malik, A., et al., 2020. Oxidative stress and inflammatory markers in type 2 diabetic patients. European journal of clinical investigation, 50 (6), e13238.
   PubMed Web of Science ®Google Scholar
• Mato Mofo, E., Essop, M., and Owira, P., 2020. Citrus fruit-derived flavonoid naringenin and the expression of hepatic organic cation transporter 1 protein in diabetic rats treated with metformin. Basic & clinical pharmacology & toxicology, 127 (3), 211–220.
   PubMed Web of Science ®Google Scholar
• Matsunaga, N., et al., 2018. Sandwich-cultured hepatocytes for mechanistic understanding of hepatic disposition of parent drugs and metabolites by transporter-enzyme interplay. Drug metabolism and disposition, 46 (5), 680–691.
   PubMed Web of Science ®Google Scholar
• Montastruc, F., et al., 2019. Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase®. Fundamental & clinical pharmacology, 33 (1), 108–112.
   PubMedGoogle Scholar
• Navarro-Gonzalez, J., et al., 2010. Serum and gene expression profile of tumor necrosis factor-alpha and interleukin-6 in hypertensive diabetic patients: effect of amlodipine administration. International journal of immunopathology and pharmacology, 23 (1), 51–59.
   PubMed Web of Science ®Google Scholar
• Nie, X., et al., 2016. Rutaecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating the irs-1/pi3k/akt and ampk/acc2 signaling pathways. Acta pharmacologica sinica, 37 (4), 483–496.
   PubMed Web of Science ®Google Scholar
• Noh, J., Park, C., and Yokozawa, T., 2011. Treatment with oligonol, a low-molecular polyphenol derived from lychee fruit, attenuates diabetes-induced hepatic damage through regulation of oxidative stress and lipid metabolism. The British journal of nutrition, 106 (7), 1013–1022.
   PubMed Web of Science ®Google Scholar
• Nowicki, M., et al., 2008. Renal and hepatic transporter expression in type 2 diabetic rats. Drug metabolism letters, 2 (1), 11–17.
   PubMedGoogle Scholar
• Palmer, S. and Strippoli, G., 2018. Metformin as first-line treatment for type 2 diabetes. The Lancet, 392 (10142), 120.
   PubMed Web of Science ®Google Scholar
• Pandya, K. and Lau-Cam, C., 2019. Taurine improves the actions of metformin and lovastatin on plasma markers of carbohydrate and lipid dysfunction of diabetic rats. Advances in experimental medicine and biology, 1155, 87–99.
   PubMed Web of Science ®Google Scholar
• Patel, O., et al., 2019. Pharmacokinetic interaction of green rooibos extract with atorvastatin and metformin in rats. Frontiers in pharmacology, 10, 1243.
   PubMed Web of Science ®Google Scholar
• Samardzic, I. and Bacic-Vrca, V., 2015. Incidence of potential drug-drug interactions with antidiabetic drugs. Die pharmazie, 70 (6), 410–415.
   PubMed Web of Science ®Google Scholar
• Seifter, S. and Dayton, S., 1950. The estimation of glycogen with the anthrone reagent. Archives of biochemistry, 25 (1), 191–200.
   PubMedGoogle Scholar
• Sheikh, M., et al., 2019. Evaluation of the secondary complications in patients of type-ii diabetes mellitus (tiidm) on allopathic, alternative or combination of medicine system: a cross sectional study. Pakistan journal of pharmaceutical sciences, 32 (6), 2817–2821.
   PubMedGoogle Scholar
• Shin, E., et al., 2017. High-dose metformin may increase the concentration of atorvastatin in the liver by inhibition of multidrug resistance-associated protein 2. Journal of pharmaceutical sciences, 106 (4), 961–967.
   PubMed Web of Science ®Google Scholar
• Shu, Y., et al., 2008. Effect of genetic variation in the organic cation transporter 1, oct1, on metformin pharmacokinetics. Clinical pharmacology & therapeutics, 83 (2), 273–280.
   PubMed Web of Science ®Google Scholar
• Silva, M., et al., 2004. Valproyl-dephosphocoa: a novel metabolite of valproate formed in vitro in rat liver mitochondria. Drug metabolism and disposition, 32 (11), 1304–1310.
   PubMed Web of Science ®Google Scholar
• Tian, K., Li, J., and Xu, S., 2019a. Rutaecarpine: a promising cardiovascular protective alkaloid from evodia rutaecarpa (wu zhu yu. ). Pharmacological research, 141, 541–550.
   PubMed Web of Science ®Google Scholar
• Tian, X., et al., 2019b. Enhanced anti-diabetic effect of berberine combined with timosaponin b2 in goto-kakizaki rats, associated with increased variety and exposure of effective substances through intestinal absorption. Frontiers in pharmacology, 10 (19), 19.
   PubMedGoogle Scholar
• Toyama, K., et al., 2012. Loss of multidrug and toxin extrusion 1 (mate1) is associated with metformin-induced lactic acidosis. British journal of pharmacology, 166 (3), 1183–1191.
   PubMed Web of Science ®Google Scholar
• Uzayisenga, R., Ayeka, P., and Wang, Y., 2014. Anti-diabetic potential of panax notoginseng saponins (pns): a review. Phytotherapy research, 28 (4), 510–516.
   PubMed Web of Science ®Google Scholar
• Wagner, D., Hu, T., and Wang, J., 2016. Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. Pharmacological research, 111, 237–246.
   PubMed Web of Science ®Google Scholar
• Wang, C., et al., 2017. Rutaecarpine alleviates renal ischemia reperfusion injury in rats by suppressing the jnk/p38 mapk signaling pathway and interfering with the oxidative stress response. Molecular medicine reports, 16 (1), 922–928.
   PubMed Web of Science ®Google Scholar
• Xu, Y., et al., 2018. Rutaecarpine inhibits intimal hyperplasia in a balloon-injured rat artery model. Chinese journal of integrative medicine, 24 (6), 429–435.
   PubMed Web of Science ®Google Scholar
• Yim, S., et al., 2017. Multidrug and toxin extrusion protein 1-mediated interaction of metformin and scutellariae radix in rats. Xenobiotica, 47 (11), 998–1007.
   PubMed Web of Science ®Google Scholar
• Yu, C., et al., 2019. Fighting type-2 diabetes: present and future perspectives. Current medicinal chemistry, 26 (10), 1891–1907.
   PubMed Web of Science ®Google Scholar
• Zhai, L., et al., 2017. Metformin ameliorates podocyte damage by restoring renal tissue nephrin expression in type 2 diabetic rats. Journal of diabetes, 9 (5), 510–517.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., et al., 2017. Co-delivery of evodiamine and rutaecarpine in a microemulsion-based hyaluronic acid hydrogel for enhanced analgesic effects on mouse pain models. International journal of pharmaceutics, 528 (1–2), 100–106.
   PubMed Web of Science ®Google Scholar